Morbid Obesity. Overweight and obesity
Conditions
Interventions
Intervention 1: Control group: Enoxaparin (Alborz Darou) 40 mg is injected subcutaneously every 12 hours for 14 days. Intervention 2: Intervention group: Rivaroxaban (Abidi) tablets 10 mg daily for 14
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients aged 18-65 years Patients with morbid obesity (body mass index >40 in people without underlying disease or >35 in patients with chronic underlying disease such as type 2 diabetes or cardiovascular disease and are candidates for bariatric surgery)
Exclusion criteria
Exclusion criteria: History of allergy to rivaroxaban, apixaban and enoxaparin use of drugs that interact with the studied drugs, such as CYP3A4 inducers (such as carbamazepine, rifampin, phenobarbital, etc.) history of any venous thromboembolism history of any cerebral or gastrointestinal bleeding or severe bleeding with no cause History of any genetic bleeding disease (such as hemophilia) or diseases predisposing to coagulability (such as Leiden factor V deficiency) Severe renal or liver failure History of uncontrolled neurological and psychiatric diseases Blood platelets less than 100,000 smoking or addiction pregnancy open bariatric surgery unwillingness to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Deep vein thrombosis. Timepoint: Before surgery and within 30 days after surgery. Method of measurement: Color doppler ultrasound of the veins of the lower limbs on both sides.;Pulmonary emboli. Timepoint: within 30 days after surgery. Method of measurement: In case of tachycardia, shortness of breath or symptoms of pulmonary embolism, patients undergo CT angiography of pulmonary vessels. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactIman Ansari
Shahid Beheshti University of Medical Sciences
Outcome results
None listed